Vitamin D status can affect COVID-19 outcomes also in pediatric population
Autor: | Michele Miraglia del Giudice, Cristiana Indolfi, Giulio Dinardo, Fabio Decimo, Alberto Decimo, Angela Klain |
---|---|
Přispěvatelé: | Miraglia Del Giudice, Michele, Indolfi, Cristiana, Dinardo, Giulio, Decimo, Fabio, Decimo, Alberto, Klain, Angela |
Rok vydání: | 2022 |
Předmět: |
RAS
renin-angiotensin system ACE2 angiotensin-converting enzyme 2 PRRs pattern recognition receptor TNF-α tumor necrosis factor-α PAMPs pathogen-associated molecular pattern RCTs randomized control trial Pharmacology (medical) Vitamin D Treg cells CD regulatory T cellcluster of differentiation Children RR risk ratio IgE immunoglobulin E DAMPs damage-associated molecular pattern TLRs Toll-like receptor Pharmacology IFN-γ reduce interferon-gamma HR Hazard Risk SARS-CoV-2 infection Immunity COVID-19 MD mean difference ICU intensive care unit IL interleukin VDRs vitamin D receptor CI confidence interval OR odds ratio DCs dendritic cell NK natural killer Food Science |
Zdroj: | PharmaNutrition. 22:100319 |
ISSN: | 2213-4344 |
DOI: | 10.1016/j.phanu.2022.100319 |
Popis: | Background: vitamin D influences the immune system and the inflammatory response. It is known that vitamin D supplementation reduces the risk of acute respiratory tract infection. In the last two years, many researchers have investigated vitamin D's role in the pathophysiology of COVID-19 disease. Results: the findings obtained from clinical trials and systematic reviews highlight that most patients with COVID19 have decreased vitamin D levels and low levels of vitamin D increase the risk of severe disease. This evidence seems to be also confirmed in the pediatric population. Conclusions: further studies (systematic review and meta-analysis) conducted on children are needed to confirm that vitamin D affects COVID-19 outcomes and to determine the effectiveness of supplementation and the appropriate dose, duration and mode of administration. |
Databáze: | OpenAIRE |
Externí odkaz: |